* Aquestive Therapeutics Inc AQST.OQ reported a quarterly
adjusted loss of 11 cents per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of -23 cents. The mean expectation of
six analysts for the quarter was for a loss of 8 cents per
share. Wall Street expected results to range from -11 cents
to -4 cents per share.
* Revenue rose 23.6% to $13.21 million from a year ago;
analysts
expected $11.63 million.
* Aquestive Therapeutics Inc's reported EPS for the quarter
was a
loss of 12 cents.
* The company reported a quarterly loss of $8.11 million.
* Aquestive Therapeutics Inc shares had risen by 106.9% this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"
Wall Street's median 12-month price target for Aquestive
Therapeutics Inc is $6.50
This summary was machine generated from LSEG data March 6 at
12:13 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.08 -0.11 Missed
Sep. 30 2023 -0.11 -0.03 Beat
Jun. 30 2023 -0.12 -0.10 Beat
Mar. 31 2023 -0.19 -0.12 Beat